Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up

F. Crippa, F. Villani, E. Bombardieri, G. L. Buraggi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-four patients with advanced breast cancer were studied with serial determinations of the radionuclide ejection fraction at rest (RST-LVEF) during anthracycline chemotherapy (CT) and with a mean follow-up (FU) of 8 months. We had 2 cases of anthracycline congestive heart failure (CHF) during FU, 3 and 12 months respectively after the end of CT. The RST-LVEF changes observed during CT were not able to predict which patients were to develop a symptomatic cardiomyopathy. The type of RST-LVEF change that is generally considered a worsening of cardiac performance is a decline ≥ 15%. We had this type of RST-LVEF change, in addition to the 2 CHF, in 5 other patients without symptomatic cardiomyopathy. Nevertheless none of these 5 patients attained pathological values of RST-LVEF, while the 2 CHF showed symptomatic cardiomyopathy only when RST-LVEF became clearly pathologic (≤ 46%). Therefore, although in our study the RST-LVEF changes during CT did not have predictive value for CHF, the method may give a notable clinical contribution all the same. In fact, by submitting the patients with a RST-LVEF fall ≥ 15% to frequent sequential RST-LVEF determinations and stopping the CT if the RST-LVEF becomes pathologic it is possible to avoid severe and irreversible CHF.

Original languageEnglish
Pages (from-to)469-475
Number of pages7
JournalTumori
Volume71
Issue number5
Publication statusPublished - 1985

Fingerprint

Epirubicin
Radioisotopes
Doxorubicin
Heart Failure
Drug Therapy
Cardiomyopathies
Anthracyclines
Therapeutics
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up. / Crippa, F.; Villani, F.; Bombardieri, E.; Buraggi, G. L.

In: Tumori, Vol. 71, No. 5, 1985, p. 469-475.

Research output: Contribution to journalArticle

Crippa, F, Villani, F, Bombardieri, E & Buraggi, GL 1985, 'Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up', Tumori, vol. 71, no. 5, pp. 469-475.
Crippa, F. ; Villani, F. ; Bombardieri, E. ; Buraggi, G. L. / Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up. In: Tumori. 1985 ; Vol. 71, No. 5. pp. 469-475.
@article{388de9e601834e73aeb99802e553f441,
title = "Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up",
abstract = "Twenty-four patients with advanced breast cancer were studied with serial determinations of the radionuclide ejection fraction at rest (RST-LVEF) during anthracycline chemotherapy (CT) and with a mean follow-up (FU) of 8 months. We had 2 cases of anthracycline congestive heart failure (CHF) during FU, 3 and 12 months respectively after the end of CT. The RST-LVEF changes observed during CT were not able to predict which patients were to develop a symptomatic cardiomyopathy. The type of RST-LVEF change that is generally considered a worsening of cardiac performance is a decline ≥ 15{\%}. We had this type of RST-LVEF change, in addition to the 2 CHF, in 5 other patients without symptomatic cardiomyopathy. Nevertheless none of these 5 patients attained pathological values of RST-LVEF, while the 2 CHF showed symptomatic cardiomyopathy only when RST-LVEF became clearly pathologic (≤ 46{\%}). Therefore, although in our study the RST-LVEF changes during CT did not have predictive value for CHF, the method may give a notable clinical contribution all the same. In fact, by submitting the patients with a RST-LVEF fall ≥ 15{\%} to frequent sequential RST-LVEF determinations and stopping the CT if the RST-LVEF becomes pathologic it is possible to avoid severe and irreversible CHF.",
author = "F. Crippa and F. Villani and E. Bombardieri and Buraggi, {G. L.}",
year = "1985",
language = "English",
volume = "71",
pages = "469--475",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Adriamycin and epirubicin treatment monitored by radionuclide ejection fraction during therapy and follow-up

AU - Crippa, F.

AU - Villani, F.

AU - Bombardieri, E.

AU - Buraggi, G. L.

PY - 1985

Y1 - 1985

N2 - Twenty-four patients with advanced breast cancer were studied with serial determinations of the radionuclide ejection fraction at rest (RST-LVEF) during anthracycline chemotherapy (CT) and with a mean follow-up (FU) of 8 months. We had 2 cases of anthracycline congestive heart failure (CHF) during FU, 3 and 12 months respectively after the end of CT. The RST-LVEF changes observed during CT were not able to predict which patients were to develop a symptomatic cardiomyopathy. The type of RST-LVEF change that is generally considered a worsening of cardiac performance is a decline ≥ 15%. We had this type of RST-LVEF change, in addition to the 2 CHF, in 5 other patients without symptomatic cardiomyopathy. Nevertheless none of these 5 patients attained pathological values of RST-LVEF, while the 2 CHF showed symptomatic cardiomyopathy only when RST-LVEF became clearly pathologic (≤ 46%). Therefore, although in our study the RST-LVEF changes during CT did not have predictive value for CHF, the method may give a notable clinical contribution all the same. In fact, by submitting the patients with a RST-LVEF fall ≥ 15% to frequent sequential RST-LVEF determinations and stopping the CT if the RST-LVEF becomes pathologic it is possible to avoid severe and irreversible CHF.

AB - Twenty-four patients with advanced breast cancer were studied with serial determinations of the radionuclide ejection fraction at rest (RST-LVEF) during anthracycline chemotherapy (CT) and with a mean follow-up (FU) of 8 months. We had 2 cases of anthracycline congestive heart failure (CHF) during FU, 3 and 12 months respectively after the end of CT. The RST-LVEF changes observed during CT were not able to predict which patients were to develop a symptomatic cardiomyopathy. The type of RST-LVEF change that is generally considered a worsening of cardiac performance is a decline ≥ 15%. We had this type of RST-LVEF change, in addition to the 2 CHF, in 5 other patients without symptomatic cardiomyopathy. Nevertheless none of these 5 patients attained pathological values of RST-LVEF, while the 2 CHF showed symptomatic cardiomyopathy only when RST-LVEF became clearly pathologic (≤ 46%). Therefore, although in our study the RST-LVEF changes during CT did not have predictive value for CHF, the method may give a notable clinical contribution all the same. In fact, by submitting the patients with a RST-LVEF fall ≥ 15% to frequent sequential RST-LVEF determinations and stopping the CT if the RST-LVEF becomes pathologic it is possible to avoid severe and irreversible CHF.

UR - http://www.scopus.com/inward/record.url?scp=0022342675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022342675&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 469

EP - 475

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -